See more : Nittoc Construction Co., Ltd. (1929.T) Income Statement Analysis – Financial Results
Complete financial analysis of Immunome, Inc. (IMNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunome, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Sierra Gold Corp. (AMNP) Income Statement Analysis – Financial Results
- NN Group N.V. (NNGPF) Income Statement Analysis – Financial Results
- WhereverTV Broadcasting Corporation (TVTV) Income Statement Analysis – Financial Results
- Index Living Mall Public Company Limited (ILM.BK) Income Statement Analysis – Financial Results
- Musashino Kogyo Co., Ltd. (9635.T) Income Statement Analysis – Financial Results
Immunome, Inc. (IMNM)
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 14.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 22.93M | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| Gross Profit | -8.91M | -631.00K | -755.00K | -755.00K | -615.00K | -521.00K |
| Gross Profit Ratio | -63.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.80M | 23.27M | 14.11M | 7.49M | 8.82M | 6.88M |
| General & Administrative | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Other Expenses | 0.00 | 0.00 | 503.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 122.82M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Cost & Expenses | 123.55M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Interest Income | 2.72M | 5.00K | 10.00K | 1.00K | 10.00K | 39.00K |
| Interest Expense | 0.00 | 5.00K | 10.00K | 38.00K | 106.00K | 141.00K |
| Depreciation & Amortization | 728.00K | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| EBITDA | -28.27M | -36.27M | -23.95M | -17.04M | -9.72M | -7.18M |
| EBITDA Ratio | -201.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.53M | -36.90M | -25.20M | -12.26M | -10.35M | -7.74M |
| Operating Income Ratio | -781.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.72M | 5.00K | 493.00K | -5.58M | -96.00K | -102.00K |
| Income Before Tax | -106.81M | -36.90M | -24.71M | -17.84M | -10.44M | -7.85M |
| Income Before Tax Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 617.00K | -242.00K | -717.00K | 106.00K | 39.00K |
| Net Income | -106.81M | -37.51M | -24.47M | -17.12M | -10.55M | -7.85M |
| Net Income Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| EPS Diluted | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| Weighted Avg Shares Out | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
| Weighted Avg Shares Out (Dil) | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
New Strong Sell Stocks for April 4th
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
Immunome: An Oncology Powerhouse In The Making
IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25. IMNM is also...
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. “2023 was a...
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. “AL102 is a...
Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
EDINBURGH, Scotland--(BUSINESS WIRE)--Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASDAQ: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its...
Immunome to Participate in the Leerink Partners Global Biopharma Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the Leerink Partners 2024 Global Biopharma Conference on...
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a targeted oncology panel at the TD Cowen...
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full...
Immunome Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the...
Immunome Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0...
Source: https://incomestatements.info
Category: Stock Reports